Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 6/2011

01-11-2011 | Clinical Investigation

Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less

Authors: Tadashi Nakano, Keiji Yoshikawa, Tairo Kimura, Hirotaka Suzumura, Mami Nanno, Takahiko Noro

Published in: Japanese Journal of Ophthalmology | Issue 6/2011

Login to get access

Abstract

Purpose

To evaluate the intraocular pressure (IOP)-reducing effects and safety of 0.0015% tafluprost ophthalmic solution (tafluprost) in normal-tension glaucoma (NTG) patients with an IOP of 16 mmHg or less.

Methods

NTG patients with a baseline IOP of 16 mmHg or less were enrolled for a one-eye study in which tafluprost was applied once daily for 12 weeks. The presence of adverse drug reactions and the cumulative incidence of adverse events were also investigated.

Results

Among the 44 enrolled patients, 41/44 (93.2%) eyes completed the study. The baseline IOP was 13.2 ± 1.3 mmHg in the study eyes and 13.0 ± 1.3 mmHg in the fellow eyes, which was not statistically significant (P = 0.9173, Student’s t test). The values obtained for IOP in the study eyes versus fellow eyes were 10.2 ± 1.6 versus 12.1 ± 1.5 mmHg at week 12. The IOP difference between the study eyes and the fellow eyes was statistically significant (P < 0.0001, Student’s t test). The cumulative incidence of adverse events was 58.5% by week 12. Ocular itching was the most frequently observed adverse event (29.3%). All adverse events were clinically tolerable.

Conclusions

Tafluprost induced significant IOP reductions in NTG patients with a baseline IOP of 16 mmHg or less without raising any safety concerns.
Literature
1.
Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi Study report 2. Ophthalmology. 2005;112:1661–9.PubMedCrossRef
2.
Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.
3.
Japan Glaucoma Society. The Japan glaucoma society guidelines for glaucoma (2nd edition). Nippon Ganka Gakkai Zasshi. 2006;110:777–814.
4.
Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye (London). 2004;18:984–9.CrossRef
5.
Kondo N, Sawada A, Yamamoto T, Taniguchi T. Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients. Jpn J Ophthalmol. 2006;50:20–4.PubMedCrossRef
6.
Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol. 2008;92:1129–33.PubMedCrossRef
7.
Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, et al. New fluoroprostaglandin F2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691–5.PubMedCrossRef
8.
Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.PubMedCrossRef
9.
Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085(tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka. 2008;25:1595–602 (in Japanese).
10.
Uusitalo H, Pillunat LE, Ropo A, On Behalf of the Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12–9.PubMedCrossRef
11.
Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97–104.PubMedCrossRef
12.
Egorov E, Ropo A, On Behalf of the Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol. 2009;19:214–22.PubMed
13.
Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436–43 (in Japanese).
14.
Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese, The Tajimi Study. Ophthalmology. 2004;111:1641–8.PubMed
15.
Yamazaki S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010;54:7–14.PubMedCrossRef
16.
Ahmed MB, William GH. One-minute Schirmer test with anesthesia. Cornea. 2003;22:285–7.CrossRef
17.
Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53:18–23.PubMedCrossRef
18.
Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand. 1995;73:233–6.PubMedCrossRef
19.
Mckibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye. 1999;13:31–4.PubMedCrossRef
20.
Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153–7.PubMedCrossRef
21.
Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma. 2006;15:238–43.PubMedCrossRef
22.
Zimmerman TJ, Stewart WC, Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19:405–15.PubMedCrossRef
23.
Kitazawa Y, Latanoprost Study Group. An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks. Rinsho Ganka (Jpn J Clin Ophthalmol). 2006;60:2047–54 (in Japanese).
24.
Honrubia F, Garacia-Sanchez J, Polo V, Martinez de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316–21.PubMedCrossRef
25.
Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010;10:4.PubMedCrossRef
Metadata
Title
Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less
Authors
Tadashi Nakano
Keiji Yoshikawa
Tairo Kimura
Hirotaka Suzumura
Mami Nanno
Takahiko Noro
Publication date
01-11-2011
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 6/2011
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-011-0082-7

Other articles of this Issue 6/2011

Japanese Journal of Ophthalmology 6/2011 Go to the issue

Letter

A case of developmental glaucoma suspected from megalophthalmos represented by obstetric ultrasonography

Laboratory Investigation

Malignant eyelid tumors in Hong Kong 1997–2009

Clinical Investigation

Anti-aquaporin-4 antibody-positive familial neuromyelitis optica in mother and daughter

Clinical Investigation

Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion

Clinical Investigation

Detection of ICP0 protein in tear fluid of individuals with active herpetic epithelial keratitis

Clinical Investigation

Correlation between cross-sectional shape of choroidal veins and choroidal thickness